证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, Aorite, Tonghe Pharmaceutical, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a 1.20% increase, surpassing the CSI 300 index by 2.57 percentage points. Sub-sectors such as innovative drugs, new medical infrastructure, and pharmacies performed well, while pharmaceutical outsourcing, medical devices, and hospitals lagged behind [6][36]. - There is a significant unmet need for Obstructive Sleep Apnea (OSA) treatment, with GLP-1RA drugs showing remarkable efficacy. The FDA approved Tirzepatide as the first and only prescription drug for treating moderate to severe OSA in adults with obesity [5][26]. Summary by Sections Industry Perspective and Investment Recommendations - OSA is linked to various health issues, including hypertension, and has a high prevalence among adults in China, with 176 million affected. The prevalence of hypertension among OSA patients is notably high [16][17]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market. The upcoming AACR and ASCO meetings are expected to catalyze interest in biotech innovations [30][31]. Industry Performance - The pharmaceutical sector's performance is highlighted, with innovative drugs and medical infrastructure leading the gains. The overall industry P/E ratio stands at 26.88, with a premium of 30.38% compared to the broader A-share market [36]. Company Dynamics - Notable company updates include: - Fuyuan Pharmaceutical reported a revenue of 3.446 billion yuan for 2024, a 3.17% increase year-on-year [37]. - Jingxin Pharmaceutical announced a share buyback totaling approximately 350 million shares [37]. - Heng Rui Medicine received approval for a new indication for its innovative drug, indicating ongoing development and regulatory progress [37].

Core Views - The report maintains a positive outlook on the biopharmaceutical industry, expecting it to outperform the market due to minimal impact from recent U.S. tariff policies on drug sectors [4][5] - The report emphasizes continued optimism for innovative drugs and sectors related to consumer recovery, highlighting the resilience of the pharmaceutical sector amidst tariff changes [4][5] Industry Insights - The recent U.S. tariff policy has a limited effect on the pharmaceutical sector, with most drugs, including various chemical drugs, vaccines, and biological products, exempt from tariffs. Raw materials like vitamins and amino acids are also on the exemption list [4][27] - The report suggests that the innovative drug sector has shown significant growth, providing a selection of quality stocks based on criteria such as strong fundamentals, potential in research pipelines, and favorable cash positions [4][5] Investment Strategy - The report recommends focusing on four main themes: "Innovation," "Going Global," "Equipment Upgrades," and "Consumer Recovery" [5] - **Innovation**: Invest in globally competitive innovative drugs and promising categories, with specific companies highlighted such as BeiGene and East China Pharmaceutical [5] - **Going Global**: Identify opportunities in overseas markets, with companies like Mindray Medical and Sinocare suggested for investment [5] - **Equipment Upgrades**: Expect support for medical equipment updates from government policies, with companies like Mindray Medical and United Imaging Healthcare recommended [5] - **Consumer Recovery**: Anticipate a rebound in sectors like ophthalmology and aesthetic medicine, with companies like Prue Eye Hospital and Tongce Medical highlighted [5] Key Companies to Watch - **Nocare Biopharma**: Expected to achieve revenue of 1.009 billion in 2024, with a 49% year-on-year growth in sales of its core product, Oubatinib [6] - **Sihuan Pharmaceutical**: Strong fundamentals with a stable performance, and a promising pipeline with multiple products expected to be approved between 2025 and 2027 [9] - **East China Pharmaceutical**: Anticipated growth driven by the commercialization of domestic nuclear medicine products and a robust R&D pipeline [10] - **China Biopharmaceutical**: Rapid revenue growth with an increasing proportion of innovative products, indicating potential for accelerated profit growth [11] - **Aier Eye Hospital**: Benefiting from growing demand in ophthalmology and favorable policies for private specialty hospitals, with significant expansion plans [21]

Group 1: Company Announcements - WuXi AppTec announced the sale of 50.8 million shares of WuXi AppTec Holdings through block trading, with a transaction amount of approximately HKD 2.178 billion, resulting in an investment gain of about RMB 1.847 billion, which accounts for over 10% of the company's latest audited net profit attributable to shareholders [1] - Jinlongyu plans to invest RMB 1.2 billion to construct a production line for key materials for solid-state batteries in Huizhou New Materials Industrial Park [2] - Dazhu CNC is conducting preliminary research on the issuance of overseas securities (H shares) and listing [3] - Anyuan Coal Industry plans to acquire 57% of Jinhui Magnetic Separation and simultaneously divest its coal business, which is expected to constitute a major asset restructuring [4] - Yuntian Lifa announced that its subsidiary has completed the delivery and acceptance of AI training and inference computing power services, positively impacting the company's operational performance [5] - AVIC Industry plans to voluntarily withdraw its A-share listing and will be suspended from trading starting April 3, 2025 [6] Group 2: Financial Performance - Naipu Mining reported a 45.46% year-on-year increase in net profit for 2024 and plans to distribute a cash dividend of RMB 0.7 per 10 shares [7] - New Hope expects a profit of RMB 430 million to RMB 500 million in the first quarter, marking a turnaround from losses [7] - Jinbei Automobile reported a net profit of RMB 382 million for 2024, a year-on-year increase of 214.06% [7] - Hailu Heavy Industry anticipates a year-on-year net profit increase of 50% to 65% for the first quarter of 2025 [8] Group 3: Major Transactions and Investments - Baiyin Nonferrous Metals completed the acquisition of a mining company's equity, increasing its copper metal resources to approximately 930,000 tons [9] - Ningbo Port expects to complete a container throughput of 12.11 million TEUs in the first quarter, a year-on-year increase of 10.9% [11] - Huafeng Communication reported a year-on-year net profit increase of 38.38% for 2024 [11] - Kid King anticipates a year-on-year net profit increase of 72.44% for 2024 and plans to distribute a cash dividend of RMB 0.5 per 10 shares [11]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.77%, outperforming the Wind All A index (1.49%) and the CSI 300 index (1.59%) [3][8] - Offline pharmacies and pharmaceutical distribution significantly outperformed the index with increases of 10.38% and 4.91% respectively, while in vitro diagnostics (0.77%), raw materials (0.83%), and other biological products (0.89%) lagged behind [3][9] - The report highlights the ongoing "Weight Management Year" initiative launched by the National Health Commission, emphasizing the need for continuous efforts in managing obesity and related chronic diseases [3][12] - The introduction of a pricing guide for brain-computer interface services by the National Medical Insurance Administration aims to accelerate the clinical application of new technologies [3][12] Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.77%, outperforming the Wind All A index (1.49%) and the CSI 300 index (1.59%) [3][8] - Key performers included offline pharmacies (10.38%) and pharmaceutical distribution (4.91%), while in vitro diagnostics (0.77%) and raw materials (0.83%) underperformed [3][9] - Top gainers included Kingmed Diagnostics (42.43%), Sanyou Medical (34.47%), and Dongfang Ocean (25%), while the largest declines were seen in Shuangcheng Pharmaceutical (-16.56%), Haichuang Pharmaceutical-U (-12.21%), and Ailis (-11.09%) [3][10] Industry News and Key Company Announcements - The National Health Commission's initiative on weight management aims to address obesity and its associated health risks, with a focus on chronic disease prevention [3][12] - The National Medical Insurance Administration has established pricing for brain-computer interface services, facilitating the transition of innovative technologies to clinical use [3][12] - Roche announced a collaboration with Zealand Pharma to develop a long-acting insulin analog, with a total transaction value of $5.3 billion [3][12] - Clinical trials for various drugs, including those for obesity and hypertension, have shown promising results, indicating potential market opportunities [3][14][16][18]

江西同和药业股份有限公司 证券代码：300636 证券简称：同和药业 公告编号：2024-056 本发明涉及的公司产品为布瓦西坦。布瓦西坦临床用于16岁以上 部分发作性癫痛的辅助治疗。 本发明提供一种新的布瓦西坦中间体化合物及其制备方法。利用 该新化合物可以制备高光学纯度的布瓦西坦，且反应条件温和、收率 高、生产成本低，适合于工业化生产。 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到中 华人民共和国国家知识产权局颁发的发明专利证书，具体情况如下： 发明名称：一种化合物及其制备方法和应用 专利号：ZL 2021 1 0345006.2 专利类型：发明专利 专利申请日：2021.03.31 授权公告日：2024.09.03 专利权人：江西同和药业股份有限公司 注：专利权自授权公告之日起生效。专利权期限为二十年，自申请日起算。 上述发明专利的取得不会对公司近期生产经营产生重大影响，但 有利于发挥公司自主知识产权技术优势，完善知识产权保护体系，从 而增强公司核心竞争力。 特此公告。 ...

关于江西同和药业股份有限公司 非经营性资金占用及其他关联资 金往来情况专项报告的鉴证报告 关于江西同和药业股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2024]第 ZA11092 号 江西同和药业股份有限公司全体股东： 我们审计了江西同和药业股份有限公司(以下简称"同和药 业")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及母公司 资产负债表、2023 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2024 年 4 月 23 日出具了报告号为信会师报字信会师报字[2024]第 ZA11090 号的无保留意见审计报告。 同和药业管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所创业板上市公司自律监管指 南第 1号——业务办理（2023 年修订）》的相关规定编制了后附的2023 年度非经营性资金占用及其他关联资金往来情况汇总表（以下简称 "汇总表"）。 编制汇总表并确保其真实、准确、合法和完 ...

江西同和药业股份有限公司 江西同和药业股份有限公司 2023 年度监事会工作报告 2023 年，江西同和药业股份有限公司（以下简称"公司"）监 事会严格依照《公司法》、《证券法》、《创业板股票上市规则》、 《上市公司自律监管指引第 2 号——创业板上市公司规范运作》及 《公司章程》、《监事会议事规则》等有关法律法规及规章制度的要 求，围绕公司年度生产经营目标切实开展了各项工作。公司全体监事 恪尽职守、勤勉尽责，对公司依法运作情况和公司董事、经理及其他 高级管理人员履行职责情况进行监督，在维护公司利益、股东合法权 益、改善公司法人治理结构、建立健全公司管理制度等工作中，发挥 了应有的作用。现将公司监事会 2023 年度主要工作报告如下： 一、2023 年度监事会主要工作 报告期内，公司监事会依法履行职责，认真进行了监督和检查。 （一）对公司经营活动的监督 监事会成员列席了 2023 年公司召开的历次董事会和股东大会会 议，听取了公司生产、经营、投资、财务等方面的工作报告，对公司 经营管理中重大决策的程序及实施情况进行了监督。在公司管理层执 行股东大会决议、董事会决议以及生产经营计划、重大投资方案、财 务决算方案 ...

证券代码：300636 证券简称：同和药业 公告编号：2024-020 江西同和药业股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求（2022 年修订）》（证监会公 告〔2022〕15 号）、《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》以及《深圳证券交易所创业板上市公 司自律监管指南第 2 号——公告格式（2023 年修订）》的相关规定， 江西同和药业股份有限公司（以下简称"公司"）就 2023 年度募集资 金存放与使用情况作如下专项报告： 一、 募集资金基本情况 (一) 募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意江西同和药业股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2023〕676 号文） 文件核准，公司向特定对象发行人民币普通股 72,926,162 股，每股 面值 1 元，发行价格 10.97 元/股，募集资金总额为 799,999, ...

上海市通力律师事务所 关于江西同和药业股份有限公司 2022 年限制性股票激励计划首次授予部分、暂缓授予部分第二个 解除限售期解除限售条件未成就及回购注销部分限制性股票的 法律意见书 致: 江西同和药业股份有限公司 敬启者: 22SH3110011/CCCC/cl/cm/D6 本所在出具本法律意见书之前已得到公司如下保证: (1)其已向本所提供了出具本法律 意见书所需全部原始书面材料或副本材料或口头陈述, 且全部文件、资料或口头陈述均是真 实、准确、完整的; (2)其已向本所提供或披露了出具本法律意见书所需全部有关事实, 且全 部事实均是真实、准确、完整的; (3)其向本所提交的各项文件、资料中的签字与印章真实有 效, 公司有关人员在本所律师调查、验证过程中所作的陈述真实有效, 所提供有关文件、资 料的复印件与原件相符; (4)其向本所提交的各项文件、资料的签署人均具有完全的民事行为 能力, 并且其签署行为已获得恰当、有效的授权。 在出具本法律意见书时, 本所假设公司: 上海市通力律师事务所(以下简称"本所")受江西同和药业股份有限公司(以下简称"同 和药业"或"公司")委托, 指派张征轶律师、蔡丛丛律师(以 ...